Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) Short Interest Update

Posted by Stephan Jacobs on Jul 17th, 2026

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT – Get Free Report) was the target of a large decline in short interest during the month of June. As of June 30th, there was short interest totaling 37,772 shares, a decline of 48.4% from the June 15th total of 73,164 shares. Currently, 2.2% of the shares of the stock are short sold. Based on an average trading volume of 299,767 shares, the days-to-cover ratio is currently 0.1 days.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen downgraded Lakewood-Amedex Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 30th.

View Our Latest Analysis on LABT

Lakewood-Amedex Biotherapeutics Price Performance

Shares of LABT stock traded up $0.04 during trading hours on Friday, reaching $1.89. 86,616 shares of the stock traded hands, compared to its average volume of 303,773. Lakewood-Amedex Biotherapeutics has a 1-year low of $1.66 and a 1-year high of $98.20. The firm has a fifty day moving average of $7.75. The firm has a market capitalization of $3.31 million and a price-to-earnings ratio of -0.94.

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT – Get Free Report) last posted its quarterly earnings data on Friday, May 22nd. The company reported ($2.00) EPS for the quarter.

Lakewood-Amedex Biotherapeutics Company Profile

(Get Free Report)

We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide.